Activator I+II (2 x 9.5 ml) - 5-plate
Activator I+II (2 x 9.5 ml)
- Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination.
- Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.
- Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
- Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.